poR2 in liver (13, 32) . In most cancer cells both receptors appear to be expressed, and several signaling pathways have been proposed as possible mediators of adiponectin biological effects in cancer cells (3, 14, 16, 19, 23, 35, 40, 56, 60, 61) . The intracellular targets of these signaling cascades are mostly unknown, with the exception of a handful of key enzymes related to lipid metabolism, such as acetyl-CoA carboxylase, which is inactivated by adiponectin through serine phosphorylation mediated by 5=-adenosine monophosphate-activated protein kinase (AMPK) (57, 64) . In addition, it is likely that adiponectin's action involves the regulation of a complex pattern of gene expressions. More than 1,000 genes are modulated in murine macrophages after 60 min of incubation with a recombinant globular form of adiponectin added at high concentration (20 g/ml) (33) . This observation suggested that the characterization of the global transcription network regulated by adiponectin could be a powerful approach to better understanding the mechanisms of action of this hormone in cancer cell lines. We designed the present study to decipher the transcription network commonly induced by adiponectin in three different human cancer-derived cell lines. These cell models (HepG2, HeLa, and Panc01) were chosen because published data showed an effect of adiponectin on their proliferation and/or survival, they all express AdipoR1 and AdipoR2, they can be cultured and treated under similar conditions, and they represent relevant experimental cell models of well-known target tissues of adiponectin. To decipher the early response cells were incubated for 3 h with full-length recombinant human adiponectin containing ϳ70% HMW forms and used at low physiological concentrations (2.5 g/ml). Using a global transcriptomic approach, we provide here the first comprehensive list of adiponectin target genes in human cancer cell lines and we attempt to characterize its mechanism of action at the transcription level through bioinformatic analyses of the regulated genes.
MATERIALS AND METHODS
Cell culture and adiponectin treatments. The three cancer-derived cell lines HeLa, Panc01, and HepG2 were provided from the European Collection of Cell Cultures (ECACC, Salisbury, UK). Cells were grown at 37°C and 5% CO 2 in DMEM with 4.5 g/l glucose containing 10% fetal calf serum, complemented with 100 g/ml streptomycin and 100 U/ml penicillin. When cells reached a concentration of 5 ϫ 10 6 cells/ well (6-well plates) they were serum depleted over 2 h in serum-free DMEM with or without AMPK inhibitor compound C (10 g/ml, Sigma Aldrich, Saint-Quentin Fallavier, France), 3 h before incubation in the presence or absence of inhibitor, with either 2.5 or 10 g/ml of full-length recombinant human adiponectin (BioVendor, Heidelberg, Germany), 1 mM aminoimidazole carboxamide ribonucleotide (AICAR), or 1 M oligomycin (Sigma). Three wells for each sample were pooled, and total RNA extraction was performed according to a standard protocol (Qiagen Quick prep mRNA, Qiagen, Microarray data analysis. The oligonucleotide microarrays produced by RNG consisted of 25,342 oligonucleotides of 50-mers printed on glass slides. TIFF images were analyzed with Genepix Pro 4.0 software (Axon Instruments). Signal intensities were log-transformed, and normalization was performed by the intensity-dependent Lowess method. Data were analyzed with the one-class significance analysis of microarray (SAM) procedure (59) . Microarray data are available in the GEO database under number GSE14070 (http:// www.ncbi.nlm.nih.gov/geo/). Bioinformatic analysis of functional enrichments [Gene Ontology (GO) pathways: biological processes, molecular functions, and cellular components] was performed by comparing the list of adiponectin-regulated genes to the human genome by means of Fisher's exact test with FatiGO ϩ software. Disease-linked information was retrieved with Marmite software (http://www.fatigo.org) (1) . Dendrograms were constructed with CLUSTER (hierarchical clustering) and TREEVIEW software (17) . Determination of signaling pathways and transcription factors that could be involved in the modulation of gene expressions by adiponectin was either performed by comparison with other experimental data sets obtained from previous microarray studies in human cells and/or implemented by bibliographic compilations of cancer-linked target genes for transcription factors in the TRED database (http://rulai. cshl.edu/cgi-bin/TRED/tred.cgi?process‫؍‬home).
Quantification of specific mRNA by real-time RT-PCR. Firststrand cDNAs were synthesized from 500 ng of total RNA in the presence of 100 U of SuperScript II (Invitrogen-Life Technologies, Eragny, France) and random hexamers and oligo(dT) primers (Promega, Charbonnières, France). Real-time PCR was performed with ABsolute QPCR SYBR Green ROX Mix (Abgene, Courtaboeuf, France) and a Rotor-Gene 6000 system (Corbett Life Science). Fold changes (stimulated vs. control) were normalized with hypoxanthine phosphoribosyltransferase 1 (HPRT1). Primer sequences and experimental conditions are provided in Supplemental  Table S1 . 1 All experiments were repeated at least three times in duplicate, and data are presented as means Ϯ SE.
RESULTS
The human adiponectin used in the study is a commercial full-length recombinant protein containing a mixture of HMW species (70%) and hexamers (25%) produced in a human embryonic kidney cell line (HEK293) (BioVendor). The aim of the study was to identify early response genes commonly regulated by adiponectin treatment in the different cancer cell lines. To this aim, cells were incubated for a short incubation period (3 h) with 2.5 g/ml adiponectin in serum-depleted medium. In preliminary experiments performed to set up the experimental conditions, we observed that the expression of the two isoforms of adiponectin receptors is strongly affected by the duration of serum deprivation. There was a significant increase in AdipoR1 and AdipoR2 mRNA levels after 18 h of serum deprivation in HeLa cells, while AdipoR2 expression was markedly reduced in HepG2 already after 9 h of starvation. We found, in contrast, that after 3 h of serum deprivation there was no modification of adiponectin receptor expression, and thus we decided to performed the experiments in cells starved for 2 h.
Identification of genes commonly regulated by adiponectin in HeLa, HepG2, and Panc01 cells. Genes with fold changes Ն95th percentile of genes based on the magnitude of the fold changes were considered as significantly regulated after corrections for multiple testing (4, 52) . After 3 h of adiponectin treatment, 661 up-and 640 downregulated probes were found commonly modulated in these cancer cells (Supplemental Table S2 ). We made quantitative RT-PCR (qRT-PCR) validations of a subset of these genes. HPRT1 was found to be the most reliable reference gene and thus was used for PCR data normalization. Adiponectin mRNA was detected at very low levels in the three cell lines (not shown). We also confirmed the expression of AdipoR1 and AdipoR2, the two receptors of adiponectin, in the three cell lines and found that treatment with adiponectin did not modify their expression levels. Then, as shown in Table 1 , validation by qRT-PCR confirmed the induction by adiponectin of hairy and enhancer of split 1 (Drosophila) (HES1) in the three cell lines, in addition to the regulation of several other genes, either downregulated (i.e., CAT in Panc01 and HepG2 and ApoC3 in HepG2) or upregulated (i.e., MAP4K4 and PDE4D in HeLa and IK-BKAP and PSMA4 in HepG2). Because of the very low mRNA levels of these genes in the different cell types in the basal situation, we were not able to accurately confirm their regulation by adiponectin in the three cell lines in parallel by qRT-PCR.
Function of genes commonly regulated by adiponectin in HeLa, HepG2, and Panc01 cells. Using KEGG and GO annotations to assign functions to the genes regulated by adiponectin, we found that the list of genes upregulated by the hormone was enriched in genes coding for proteins involved in immune and stress responses as well as cell proliferation and mainly located in the nuclear cellular compartment ( Table  2 ). The list of downregulated genes was enriched in genes involved in translation (eukaryotic 48S initiation and 43S preinitiation complexes) or involved in ribosomal structure and function.
Among the regulated genes in the three cancer-derived cell lines, we then wished to determine those that could be directly related to cancer by using MARMITE from Babelomics (http://bioinfo.cipf.es/babelomicswiki/tool:marmite) to perform functional enrichment tests using text mining-derived gene modules based on PubMed document analysis. This analysis resulted in a group of 211 genes regulated by adiponectin, which were related to cancers and tumor processes including neoplasms (82% of them), malignant neoplasms (66%), and more specifically malignant neoplasms of breast (40%) ( Figs. 1 and 2 ). Biological function analysis revealed that 21% of the upregulated genes were involved in regulation of cell proliferation (GO: 0008283) and 11.4% of the downregulated genes in the constitution and function of ribosomes.
Biological pathways significantly overrepresented in lists of genes regulated by adiponectin in HeLa, HepG2
, and Panc01 cells. Adiponectin has pleiotropic effects by interfering with many cellular signaling pathways. In an attempt to identify those that might be involved in regulation of transcription in cancer-derived cell lines, we compared the list of adiponectinresponsive genes with 33 different published gene lists established from previous microarray experiments, targeting specific intracellular signaling cascades (Table 3) exclusively on human cells, and usually with cancer cells (Supplemental Table S4 ). Pathways significantly overrepresented in the lists of genes regulated by adiponectin were selected on the bases of Z-score calculation (confidence level Ͼ 0.90). About 30% of the genes regulated by adiponectin in our experimental conditions were also found modulated by at least one of these pathways. Among the genes that were upregulated by adiponectin, we found a significant enrichment in genes known to be modulated by several hormones and ligands, such as insulin, IGF II, bone morphogenic protein (BMP), hepatocyte growth factor (HGF), IFN-␣, TNF-␣, or vitamin D, as well as genes regulated by JNKs, serine/threonine kinase 11 (LKB1), and/ or phosphatidylinositol 3-kinase (PI3K) signaling cascades (Table 4) . Downregulated genes were significantly enriched in genes modulated by fatty acids, Ki-Ras, and tuberous sclerosis complex 1 and 2 (TSC1/2).
Activation of LKB1/AMPK signaling pathway in HepG2 cells treated with adiponectin. AMPK is thought to be one of the major intracellular effectors of adiponectin signaling. Two microarray studies have previously described the gene network regulated by AMPK. These results were obtained either by overexpressing AMPK in rat pancreatic islets (15) or by invalidating FOXO3a, one of the main AMPK effectors in mouse embryonic fibroblasts (22) . When we compared the lists of genes retrieved from these two experiments with our list of genes regulated by adiponectin in the three cancer cell lines, we could not find common genes. This discrepancy might result from the different experimental conditions (e.g.. rodent vs. human cells, normal vs. cancer-derived cells, gene manipulation vs. short incubation with hormone). Thus to verify whether activation of the LKB1/AMPK pathway might contribute to the transcriptional action of adiponectin in the three tested cancer cell lines and under our experimental conditions (low dose of adiponectin and short-term stimulation), we used oligomycin to stimulate LKB1 (upstream effector of AMPK), AICAR as a direct AMPK activator, and compound C as an AMPK pathway inhibitor. For these experiments, cells were incubated in serum-free media with or without compound C for 2 h before addition of adiponectin (2.5 g/ml or 10 g/ml), AICAR, or oligomycin for 3 h before cell lysis and gene expression analysis. Because cell treatment with AMPK modulators was not initially included in the microarray study, we decided to test this pathway by measuring the regulation of specific genes with qRT-PCR, and more especially of HES1, one of the most upregulated gene by adiponectin in the three cell lines on microarray and correctly validated by real-time PCR (Table 1 ). Figure 3 clearly shows that AICAR and oligomycin reproduced the effect of adiponectin on HES1 expression in HepG2, while compound C completely counteracted it. The contribution of the LKB1/AMPK pathway in the effect of adiponectin on HES1 expression was also confirmed in HeLa and Panc01 cells, where we found results similar to those in HepG2 (data not shown). EGR1 (early growth responsive 1), a well-known target gene of the LKB1/AMPK pathway, was strongly induced by AICAR (8.6 Ϯ 4.2-fold) and oligomycin (50 Ϯ 14-fold) in HepG2 cells. In contrast, the expression of CAT (catalase) gene, which was significantly downregulated by adiponectin treatment (Table 1) , was not affected by oligomycin (1.03 Ϯ 0.98-fold) but strongly reduced by AICAR (0.52 Ϯ 0.01 fold). Of note, we verified in the three cell lines that neither AdipoR1 nor AdipoR2 was affected by AICAR or oligomycin action (data not shown), in agreement with the lack of effect of adiponectin. Together, these results indicate that the classical LKB1/AMPK pathway is likely involved, at least in part, in the short-term effects of adiponectin on gene expression in cancer cells.
Analysis of promoter regions of genes regulated by adiponectin and identification of putative transcription factors involved.
In a first step, using FatiGO ϩ , the promoter regions of the genes regulated by adiponectin were scanned for the presence of transcription factor DNA binding motifs. qRT-PCR fold changes Ϯ SE were normalized to HPRT1 (hypoxanthine phosphoribosyltransferase 1) mRNA levels. Table 5 indicates that these genes were enriched in binding motifs for CCAAT/enhancer binding protein ␥ (CEBPG), Caudal type homeobox 2 (Cdx-2), hepatocyte nuclear factor (HNF1), and E2F-myc activator/cell cycle regulators (E2F).
We also found significant enrichment in binding motifs for transcription cofactor Coiled-coil domain containing 59 (Cdc5). In a second step, the list of genes modulated by adiponectin was compared with lists of genes regulated by various transcription factors (47 different transcription factors) obtained from previous published microarray experi- (66), and liver and liver cell line steatosis (12) . A: among adiponectin-regulated genes, 211 were found to be associated with 34 different disorders. B: subgroup of genes that are commonly dysregulated in most disorders. FatiGO ϩ functional enrichment analysis (Fisher's exact test, P value Ͻ 0.05) of genes regulated by adiponectin by comparing respectively the 661 upregulated and 640 downregulated genes retrieved from microarray analysis to the global list of 20,839 genes commonly detected in cancer cells HeLa, HepG2, and Panc01. Values indicated in parentheses were not used for P value calculation. GO, Gene Ontology. 
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Physiol Genomics • VOL 42A • www.physiolgenomics.org ments performed exclusively with human cells (Table 6 and Supplemental Table S5 ). We postulated that the common regulated genes would indicate a direct or indirect implication of one of these transcription factors in the transcriptional action of adiponectin. Among genes regulated by adiponectin, 33.3% of the upregulated and 32% of the downregulated genes were also regulated by at least one of the considered transcription factors ( Table 2 , Fig. 1 ). The transcription factor or/and cofactor gene lists that were significantly enriched in genes regulated by adiponectin were involved in two major cell biological functions: 1) control of cell proliferation, cell cycle, and cell growth (i.e., Cdc5, Cdx-2, E2F, Foxo1A, KLF4, MYC, PPARg, RXRs, SREBP1a and EGR1) and 2) metabolism (i.e., Foxo1a, PPARa, PPARg, RXRs, USFs and SREBP1a). Several of these transcription factors are known to regulate each other and to have DNA binding motifs in promoter regions of the same genes. For example, the gene coding for CAT is known to be regulated by PPARs (43, 55) , E2Fs (51), and EGR1 (43) .
DISCUSSION
Many recent studies have shown that the fat-derived hormone adiponectin could be considered as a potential anticancer agent. For example, proliferation of prostate cancer cells has been reported to be inhibited by adiponectin in isoform-, time-, and dose-dependent manners, with a higher effectiveness for full-length adiponectin (less than 1 g/ml) than globular (truncated monomer) adiponectin (more than 1 g/ml) (7). In a very recent study, it was shown that adiponectin (10 g/ml) inhibits proliferation of MCF-7 human breast cancer cells (30) . Despite Only significant signaling pathways overrepresented in the list of genes modulated by adiponectin are listed here (Z-score confidence level Ͼ 0.90). Full data and references are provided in Supplemental Table S4 . *Data validated by experiments on HepG2 cells. BMP, bone morphogenic protein; HGF, hepatocyte growth factor; IGF2, insulin-like growth factor II; INF-␣, interferon-␣; JNK, janus kinases; LKB1, serine/threonine kinase 11; PTEN, phosphatase and tensin homolog; TNF-␣, tumor necrosis factor-␣; TSC1/2, tuberous sclerosis complex 1 and 2. For gene names, see Supplemental Table S2 .
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Physiol Genomics • VOL 42A • www.physiolgenomics.org this large bulk of data, the mechanism of action of adiponectin at the molecular level in cancer cells remains largely elusive. One of the strategies to increase our knowledge in this field is to characterize the transcriptional regulations induced by adiponectin in order to retrieve novel molecular information, which will help explain the biological action of this important hormone. Therefore our aim in the present study was to identify early target genes of adiponectin in different cancerderived cell lines. Liver HepG2, pancreatic Panc01, and cervical HeLa cells were treated with a low physiological concentration of recombinant human full-length adiponectin, containing mainly the HMW forms. These cell lines were selected on the basis of literature reports on adiponectin action, the presence of both adiponectin receptors AdipoR1 and AdipoR2, and common culture conditions. We found that adiponectin produces profound changes in mRNA levels and identified 1,301 genes commonly modulated in the three cancer cell types during short exposure. Recently, a microarray study in rodent macrophages also revealed a large number of regulated genes by using globular adiponectin at higher concentration (20 g/ml) (33) . Except for this recent study, few genes have been reported to be regulated by adiponectin at the transcriptional level in human cells or tissues. These include AOX1 (44) and LPL (36) , which have been found to be regulated by globular adiponectin, and MCP-1 and IL8 regulated by both globular and full-length adiponectin (53, 58) . In our study, AOX1 and LPL were not affected by treatment with full-length adiponectin, while MCP-1 was commonly regulated in the three cancer cell lines.
Our data provide a comprehensive, large list of genes acutely regulated by the full recombinant protein in human cancer-derived cell lines. These genes are mainly involved in functions directly related to fundamental biological processes known to be affected in cancer, such as immune response, cell proliferation, response to stress, and regulation of ribosomal structure and function. Furthermore, using a text mining approach based on PubMed publication analysis, we found that the adiponectin-regulated genes appeared to be associated with various disorders, but more specifically with malignant forms of neoplasms.
Bioinformatic analyses revealed that multiple pathways could contribute to the network of modulated genes, including the PI3K signaling pathway known to be involved in insulin and growth factor actions, and also the LKB1/AMPK signaling pathway. These signaling cascades have previously been proposed to be central mediators of tumor suppression (26, 34) , and adiponectin has been clearly described as an activator of the LKB1/AMPK pathway (35) . This was also confirmed in our study by a focused experiment on HES1 gene in HepG2 cells. However, in addition to these expected pathways, analysis of genes commonly regulated in Panc01, HepG2, and HeLa cells supports the hypothesis that adiponectin can modulate the expression of some genes independently from the LKB1 pathway. JNK2 and p70S6 kinase activation might also be involved, as previously proposed in various studies (31, 40, 62) .
Regarding the transcription factors potentially involved in adiponectin action on gene expression, promoter analysis of the regulated genes revealed a large list of enriched transcription factor binding sites. Several of these have been previously shown to be regulated by adiponectin, such as PPARa (44, 67) or Foxo1a (9) , suggesting that they can be potential mediators of its transcriptional action. Interestingly, our analysis also revealed potential implication of SREBP1, known to be activated by insulin signaling via PI3K (20) . SREBP1s are also important transcription factors in the control of lipid and cholesterol metabolism (38, 54) . Furthermore, independent experiments have shown that LKB1 and SREBP1a inhibit cell growth (28) . Altogether these observations converge to support the hypothesis that adiponectin modulates known cellular pathways at the crossroad between metabolism and cell proliferation.
Adiponectin-regulated genes are also enriched in binding sites for MYC. Myc expression and activity are altered in most, if not all, cancers (48) . In breast cancer cells, activation of the Table S3 . Fig. 3 . Regulation of hairy and enhancer of split 1 (Drosophila) (HES1) gene expression by full-length recombinant human adiponectin and by serine/ threonine kinase 11 (LKB1)/5=-adenosine monophosphate-activated protein kinase (AMPK) activators [aminoimidazole carboxamide ribonucleotide (AICAR) and oligomycin] and inhibitor (compound C). Data are expressed as fold change in mRNA levels of HES1 vs. control condition and after standardization of the data by hypoxanthine phosphoribosyltransferase 1 (HPRT1) mRNA levels. Experimental conditions are described in the text, and mRNA levels were determined by quantitative RT-PCR (qRT-PCR). Briefly, HepG2 cells were maintained for 2 h in serum-free media with or without inhibitor; activators were then added for 3 h before cell lysis. LKB1/AMPK pathway by adiponectin leads to reduced cell proliferation, migration, and invasion, by decreasing MYC and cyclin D1 action (14, 56) . It has been demonstrated that MYC regulates the transcription of several ribosomal proteins (6, 10, 37) , and a number of these were found to be downregulated by adiponectin in our work. Interestingly, regulation of ribosome structure and function is now known to contribute to neoplasic transformation (18, 41) .
In summary, the present transcriptomic study allowed the identification of 1,301 genes commonly modulated in three cancer-derived cell lines in response to short-term stimulation with full-length recombinant human adiponectin. Most of these genes are involved in malignant neoplasms, supporting the link between adiponectin and cancer mechanisms. Bioinformatic analyses demonstrated the diversity of signaling pathways and transcription factors potentially involved in adiponectin effects on gene expression, illustrating the complexity of adiponectin mechanisms of action in cancer cells. Because a beneficial effect of adiponectin on cancer cell proliferation and survival has been observed in many studies, it will be interesting to verify whether the major pathways retrieved in the present work are also involved in other cell types, for example, in breast cancer cells, which seem to be very sensitive to adiponectin (30) . Globally, our study provides novel molecular information, which will now help in understanding the biological effects of adiponectin in cancer cells and more specifically to decipher the mechanisms behind its beneficial effects on proliferation and apoptosis. Table S5 ). We then determined, among these 47 lists of genes, which of them were statistically enriched in genes also up-or downregulated by adiponectin in HeLa, HepG2, and Panc01 cells (Z-score confidence level Ͼ0.90). E2F, E2F/MYC activator/cell cycle modulators; EGR1, early growth responsive 1; KLF4, Kruppel-like factor 4; MYC, myelocytomatosis viral oncogene homolog avian; PPARA and G, peroxisome proliferator-activated receptors ␣ and ␥; RXR, retinoid receptors; SREBP1A, sterol regulatory element binding transcription fraction 1, isoform a; USF, upstream stimulatory factor. For gene abbreviations, see Supplemental Table S2 .
